Orlistat Market Report 2026

Orlistat Market Overview

• Orlistat market size has reached to $3.2 billion in 2025 • Expected to grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Obesity Rates And Their Impact On The Growth Of The Orlistat Market • Market Trend: Advancements In Weight Loss Drug Boost Orlistat Market • North America was the largest region in 2025.

What Is Covered Under Orlistat Market?

Orlistat is a medication used to aid weight loss by preventing the absorption of fats from the diet, thereby reducing calorie intake. It works by inhibiting the enzyme lipase, which is necessary for the breakdown of dietary fats in the intestine. It is typically prescribed for individuals who are obese or overweight and is most effective when combined with a low-fat diet and regular exercise. The main types of orlistat are 120 milligrams (mg) and 60 milligrams (mg). 120 mg orlistat refers to a specific dosage of the weight-loss medication orlistat, which is used to help obese patients lose weight by inhibiting the absorption of dietary fats. It is typically taken three times a day with meals containing fat. It is distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies for applications such as weight-reducing aid, and others.

What Is The Orlistat Market Growth Forecast?

The orlistat market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to expanding adoption of orlistat in emerging markets, growing preference for non-invasive obesity treatments, increasing integration of orlistat in weight management programs, rising healthcare initiatives for obesity prevention, technological advancements in formulation and delivery methods. Major trends in the forecast period include rising adoption of orlistat as a weight management therapy, increasing preference for prescription and otc orlistat formulations, growing focus on combining orlistat with lifestyle interventions, rising demand for low-fat diet-compatible weight loss solutions, increasing awareness about obesity management and preventive care.

Global Orlistat Market Segmentation

1) By Type: 120 Milligram (Mg), 60 Milligram (Mg) 2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies 3) By Application: Weight-Reducing Aid, Other Applications Subsegments: 1) By 120 Milligram (Mg): Prescription-Based 120 Mg Orlistat, Over-The-Counter (OTC) 120 Mg Orlistat 2) By 60 Milligram (Mg): Over-The-Counter (OTC) 60 Mg Orlistat, Prescription-Based 60 Mg Orlistat

What Is The Driver Of The Orlistat Market?

Increasing obesity rates are expected to propel the growth of the orlistat market going forward. Obesity is a medical condition characterized by excessive body fat accumulation, which can negatively impact health. It is commonly measured by a body mass index (BMI) of 30 or higher. Obesity is increasing due to factors such as poor diet, lack of physical activity, and sedentary lifestyles. Orlistat is used in obesity management by inhibiting the absorption of dietary fats, which helps reduce body weight and maintain weight loss. It is often prescribed alongside a reduced-calorie diet and exercise for more effective results. For instance, in 2024, according to the report published by the World Obesity Federation, a UK-based non-profit organization, by 2035, 79% of adults with overweight and obesity will live in Low- and Middle-Income Countries (LMICs) by 2035. Further, 88% of children with overweight and obesity will be living in LMICs by 2035. Therefore, increasing obesity rates are driving the growth of the orlistat industry.

Key Players In The Global Orlistat Market

Major companies operating in the orlistat market are Merck & Co. Inc., GlaxoSmithKline plc, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Dr Reddys Laboratories Ltd., Cipla Ltd., Intas Pharmaceuticals Ltd., Lupin Pharmaceuticals Inc., Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Zydus Life, Emcure Pharmaceuticals Ltd., Lannett Company Inc., Strides Pharma Science Ltd., Indoco Remedies Ltd., Wockhardt Ltd., Jubilant Life Sciences Ltd., Aurobindo Pharma Ltd.

Global Orlistat Market Trends and Insights

Major companies operating in the orlistat market are developing innovative products, such as weight loss drugs, to enhance personal hygiene and comfort through advanced technology and design. A weight loss drug refers to a medication designed to help individuals reduce body weight by suppressing appetite, increasing metabolism, or blocking fat absorption. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide) injection, a new weight loss drug. It is the first and only approved treatment that activates two incretin hormone receptors, GIP and GLP-1, addressing an underlying cause of excess weight. Zepbound is indicated for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related condition.

What Are Latest Mergers And Acquisitions In The Orlistat Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Versanis Bio for $1.93 billion. The acquisition broadens Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently under evaluation in a Phase 2b study both alone and in combination with semaglutide for adults with overweight or obesity. Versanis Bio Inc. is a US-based biotech company that develops medicines to treat medical conditions by helping overweight and obese adults.

Regional Outlook

North America was the largest region in the orlistat market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Orlistat Market?

The orlistat market consists of sales of xenical, combination supplements, and dietary aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Orlistat Market Report 2026?

The orlistat market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the orlistat industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.